Article
Obstetrics & Gynecology
Pongkarn Buasawat, Jittima Manonai, Pintip Ngamjanyaporn
Summary: The study evaluated the perception of contraceptive counseling and knowledge regarding unintended pregnancy as well as the prevalence and predictors for contraceptive use among SLE patients. Results showed that most patients did not receive contraceptive counseling, but approximately half of the patients used contraceptive methods in the past three months.
Review
Immunology
Paul Curtiss, Amanda M. Walker, Benjamin F. Chong
Summary: This study reviewed patient cohorts and populations to investigate the progression of cutaneous lupus to systemic lupus. The study found variations in the progression rates between adult and pediatric groups, which were attributed to differences in patient populations, study design, diagnostic criteria, and follow-up time. Risk factors associated with the development of systemic lupus included positive anti-nuclear antibodies, hematologic abnormalities, and a higher number of lupus classification criteria at baseline.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Immunology
Zhihui Liu, Ruijuan Cheng, Yi Liu
Summary: This study evaluated the safety of anifrolumab in patients with moderate to severe systemic lupus erythematosus (SLE). The results showed that serious adverse events were less common in the anifrolumab group compared to the placebo group. The most common adverse events included upper respiratory tract infection, nasopharyngitis, bronchitis, and herpes zoster. Anifrolumab is considered a well-tolerated option for the treatment of SLE patients with good safety.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Immunology
Nefeli Giannopoulou, Latika Gupta, Laura Andreoli, Daniele Lini, Elena Nikiphorou, Rohit Aggarwal, Vikas Agarwal, Ioannis Parodis
Summary: The study found that COVID-19 vaccination in pregnant SLE patients was safe and did not exacerbate their autoimmune disease. Minor vaccine-related adverse events were reported but did not affect daily functioning and resolved within a few days. No adverse pregnancy outcomes were reported. Overall, the risk/benefit ratio of COVID-19 vaccination in SLE patients and high-risk pregnancies is favorable.
AUTOIMMUNITY REVIEWS
(2023)
Article
Obstetrics & Gynecology
R. Gina Silverstein, Victoria Fitz, Madeline Thornton, Allison Carter, Jessica E. Morse
Summary: In a study involving 453 women of reproductive age with systemic lupus erythematosus, only 71% had documentation of contraception use, with 37% using highly effective methods. 78% received contraception counseling, but 24% had no contraception documented. 28% of patients were using contraceptives with possible or absolute contraindications.
Review
Immunology
S. Giambalvo, C. Garaffoni, E. Silvagni, F. Furini, R. Rizzo, M. Govoni, A. Bortoluzzi
Summary: This systematic literature review aimed to explore the factors associated with fertility outcomes in women of childbearing age with systemic lupus erythematosus (SLE). The study found that exposure to cyclophosphamide and its cumulative dose can impair gonadal function in SLE women, leading to amenorrhea and premature ovarian failure (POF). Certain treatments were associated with a lower risk of POF. Hormonal and serological factors did not appear to impact fertility outcomes, but could be used as surrogate markers of fertility.
AUTOIMMUNITY REVIEWS
(2022)
Article
Rheumatology
Sarah H. Chung, Kimiko Oshima, Michael Singleton, Jenna Thomason, Cara Currier, Stephen McCartney, Namrata Singh
Summary: Women with SLE are at high risk for cervical dysplasia, and this study investigated the prevalence of cervical cancer screening according to ASCCP guidelines in this population. The study found that only half of the women with SLE had guideline-congruent screening, highlighting the need for increased awareness and consensus among providers regarding SLE-specific cervical cancer screening.
JOURNAL OF RHEUMATOLOGY
(2022)
Article
Medicine, General & Internal
Fanny Urbain, Maharajah Ponnaiah, Farid Ichou, Marie Lhomme, Clement Materne, Sophie Galier, Julien Haroche, Eric Frisdal, Alexis Mathian, Herve Durand, Micheline Pha, Miguel Hie, Anatol Kontush, Philippe Cluzel, Philippe Lesnik, Zahir Amoura, Maryse Guerin, Fleur Cohen Aubart, Wilfried Le Goff
Summary: This study uncovers the contribution of disturbed metabolism to the presence of coronary artery calcium and the associated risk of coronary heart disease in patients with systemic lupus erythematosus (SLE). Identification of novel lipid and metabolite biomarkers may help stratifying patients for reducing cardiovascular disease morbidity and mortality in SLE.
Review
Pharmacology & Pharmacy
Xiaobo Li, Zhouqing He, Li Ru, Yueming Yuan, Zheng Yuan, Pengfei Chen, Zhiyong Xu, Qi Wang, Jianping Song, Qin Xu
Summary: The combination of Qinghao Biejia decoction with conventional chemical medicine shows advantages in treating SLE by improving overall response rate, reducing disease activity index and symptom scores, enhancing immunological indexes, and decreasing adverse events. However, more high-quality RCTs are needed to confirm these findings.
FRONTIERS IN PHARMACOLOGY
(2021)
Review
Medicine, General & Internal
Ya Lan Chen, Jie Meng, Cong Li
Summary: Intestinal perforation is a rare complication of systemic lupus erythematosus (SLE). This study retrospectively collected and analyzed the clinical data of 18 cases of SLE-related intestinal perforation. The results suggest that risk factors for intestinal perforation in SLE include disease duration of >5 years, SLE disease activity index score of >10, nonstandard use of steroids, and concomitant presence of other immune system diseases. Early diagnosis, aggressive resuscitation, antibiotics, steroid therapy, and prompt surgical intervention are key to successfully managing such cases.
Article
Rheumatology
Jingru Tian, Dingyao Zhang, Xu Yao, Yaqing Huang, Qianjin Lu
Summary: This study estimated the epidemiology of SLE globally, finding variations in incidence and prevalence rates across different countries and regions. It also highlighted the impact of gender, age, and prevalence estimation method on the findings. SLE was found to occur more frequently in high-income countries.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Rheumatology
Luis Lucero-Morales, Juanita Romero-Diaz, Diana Yazmin Copado-Mendoza, Maria del Carmen Zamora-Medina, Sandra Acevedo-Gallegos, Juan Manuel Gallardo-Gaona, Berenice Velazquez-Torres, Jose Antonio Ramirez-Calvo, Dulce Maria Camarena-Cabrera, Maria Jose Rodriguez-Sibaja
Summary: The study conducted a diagnostic assessment of pregnant women using a screening questionnaire for SLE, which showed high sensitivity and specificity in diagnosing SLE. The findings suggest that the questionnaire can be a useful tool in determining who requires antinuclear antibody testing and rheumatologist referral for pregnant patients.
LUPUS SCIENCE & MEDICINE
(2021)
Review
Pharmacology & Pharmacy
Xiaohong Gong, Huan Li, Hongtao Guo, Shangwen Wu, Chaoqun Lu, Yiming Chen, Songwei Li
Summary: For systemic lupus erythematosus (SLE), total glucosides of paeony (TGP) combined with different conventional therapeutic agents are more effective in reducing disease activity and incidence of adverse reactions compared to conventional treatments, although the quality of evidence is poor.
FRONTIERS IN PHARMACOLOGY
(2022)
Review
Immunology
Qian Wu, Yang Liu, Wei Wang, Yu Zhang, Kui Liu, Song-Hua Chen, Bin Chen
Summary: This meta-analysis investigates the incidence and prevalence of tuberculosis (TB) in patients with systemic lupus erythematosus (SLE). The results show that both the incidence and prevalence of TB are high among SLE patients. Subgroup analyses also reveal that the incidence is higher in Africa and countries with a high TB burden, while the prevalence is elevated in Asia, patients taking a high daily dose of glucocorticoids, studies with small sample sizes and those conducted before 2001.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Immunology
Amirhossein Azari Jafari, Mojtaba Keikha, Seyyedmohammadsadeq Mirmoeeni, Mohammad Taghi Rahimi, Reza Jafari
Summary: The study systematically reviewed the use of live parasites or parasitic products in treating mouse models of SLE, demonstrating potential immunomodulating effects on improving immunologic cells and pathological changes.
AUTOIMMUNITY REVIEWS
(2021)